Relative clinical utility of simultaneous 18F-fluorodeoxyglucose PET/MRI and PET/CT for preoperative cervical cancer diagnosis

ObjectiveTo investigate the utility of ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI) for the preoperative diagnosis of cervical cancer.MethodsWe retrospectively analyzed 114 patients who were diagnosed with cervical cancer and underwent PET/MRI (n = 59) or PET/computed tomography (PET/CT) (n = 65) before surgery. The maximal standardized uptake value (SUV_max) and mean SUV (SUV_mean) were determined for regions of interest in the resultant radiographic images.ResultsRelative to PET/CT, ¹⁸F-FDG PET/MRI exhibited higher specificity and sensitivity in defining the primary tumor bounds and higher sensitivity for detection of bladder involvement. The SUV_max and SUV_mean of PET/MRI were remarkably higher than those of PET/CT as a means of detecting primary tumors, bladder involvement, and the lymph node status. However, no significant differences in these values were detected when comparing the two imaging approaches as a means of detecting vaginal involvement or para-aortic lymph node metastasis.ConclusionsThese outcomes may demonstrate the capability of ¹⁸F-FDG PET/MRI to clarify preoperative cervical cancer diagnoses in the context of unclear PET/CT findings. However, studies directly comparing SUVs in different lesion types from patients who have undergone both PET/MRI and PET/CT scans are essential to validate and expand upon these findings.     

髓外浆细胞瘤CT、MRI及18F-FDG PET/CT表现

目的 探讨髓外浆细胞瘤（EMP）CT、MRI及¹⁸F-FDG PET/CT表现。方法 回顾性分析14例经病理证实的EMP的CT、MRI及¹⁸F-FDG PET/CT资料,观察病灶特征。结果 4例接受CT检查,病灶均以等密度为主,1例邻近骨质破坏,但无明显骨质硬化改变。7例接受MR检查,病灶信号均匀,T1WI呈等或稍低信号,T2WI以等或稍高信号为主,其中2例病灶内或周边可见流空血管影。增强扫描病灶呈均匀或不均匀中-重度强化,部分病灶边缘可见细小血管影,5例增强MRI病灶内可见强化更为显著的间隔。9例接受¹⁸F-FDG PET-CT扫描,7例表现为等密度软组织肿块或结节影,2例仅表现为局部软组织增厚伴结节状,均伴团块状中-重度放射性摄取增高,SUV最大值8.43±3.33。结论 CT、MRI及¹⁸F-FDG PET/CT在诊断EMP、鉴别诊断、指导临床治疗方案和预后评估等方面存在一定价值。     

组织细胞坏死性淋巴结炎18F-FDG PET/CT表现

目的 观察组织细胞坏死性淋巴结炎（HNL）¹⁸F-FDG PET/CT表现。方法 回顾性分析11例经病理证实HNL患者的¹⁸F-FDG PET/CT及临床表现,分区域选取¹⁸F-FDG摄取最高的病变淋巴结54枚,分析其最大径、位置与最大标准摄取值（SUV_max）的相关性。结果 11例HNL中,7例受累淋巴结呈全身性分布,4例仅颈部和/或腋窝淋巴结受累;11例颈部淋巴结均受累,9例腋窝淋巴结受累;受累淋巴结呈卵圆形,最大短径均<2.30 cm,密度多均匀,且无融合趋势;¹⁸F-FDG PET/CT显像见不同程度放射性摄取,SUV_max为1.22~23.34,中位SUV_max为5.56（2.37,9.87）。8例发热患者中,6例中轴骨摄取高于肝脏。淋巴结最大短径、最大长径均与SUV_max呈低度正相关（r=0.496,P<0.001;r=0.347,P=0.010）,所在位置与SUV_max无明显相关（r=0.019,P=0.892）。结论 HNL于¹⁸F-FDG PET/CT显像主要表现为全身多发淋巴结轻、中度肿大,颈部及腋窝淋巴结多受累及代谢增高,伴或不伴中轴骨代谢增高。¹⁸F-FDG PET/CT可用于评估HNL患者全身淋巴结受累、判断疾病活动度及辅助活检定位。     

罗萨伊-多尔夫曼病18F-FDG PET/CT表现

目的 观察罗萨伊-多尔夫曼病(RDD)¹⁸F-FDG PET/CT表现。方法 纳入6例活检病理确诊RDD患者，分析其¹⁸F-FDG PET/CT及其他常规影像学检查资料，观察RDD ¹⁸F-FDG PET/CT表现特点。结果 本组6例RDD中，1例为皮肤原发病变，3例为淋巴结内+结外病变，2例仅有淋巴结内病变；最常见的结外受累部位为骨(n=3),其次为鼻咽/鼻腔及鼻窦(n=2);PET/CT示其均呈FDG高摄取，最大标准摄取值为4.3～16.5。结论 RDD病灶¹⁸F-FDG PET/CT表现为FDG高摄取。     

骨盆功能不全性骨折18F-FDG PET/CT表现

目的 观察骨盆功能不全性骨折（PIF）¹⁸F-FDG PET/CT表现。方法 回顾性分析23例接受¹⁸F-FDG PET/CT检查的PIF患者,观察其PET/CT表现。结果 23例PIF中,17例为肿瘤患者,均未见明显骨转移;6例因排查肿瘤而接受检查,均排除肿瘤;其中20例（20/23,86.96%）为双侧、3例（3/23,13.04%）为单侧PIF,多累及骶、髂骨,少数累及耻骨;主要表现为骶骨翼或/和骶骨体或/和髂骨高密度影,部分病灶可见骨折线,累及耻骨时表现为局部骨质中断;病灶放射性摄取轻-中度增高,最大标准摄取值（SUV_max）为5.01±2.21,与肝脏血池平均标准摄取值比值（SUR-BP）为1.97±0.78。结论 ¹⁸F-FDG PET/CT中,PIF主要表现为骶骨翼或/和骶骨体或/和髂骨高密度影,部分病灶可见骨折线,累及耻骨时局部骨质中断,而无溶骨性破坏及周围软组织肿块形成,伴轻-中度放射性摄取增高,有助于与骨转移癌相鉴别。     

对比分析头颈部鳞状细胞癌PET/CT与PET/MR特征

目的 探讨头颈部鳞状细胞癌（HNSCC）的PET/CT及PET/MR特征。方法 纳入未经抗肿瘤治疗的头颈部鳞状细胞癌患者40例,所有患者均接受PET/CT及头颈部MR检查。由2名观察者独立观察PET阳性病灶,包括阳性原发灶及阳性淋巴结;并对PET/CT、PET/MR T1WI及PET/MR T2WI的图像质量、融合准确度、病灶清晰度、病灶特征等进行评分。分析2名观察者间的一致性。结果 40例患者共90个PET阳性病灶,包括阳性原发灶40个、阳性淋巴结50个。PET/CT、PET/MR T1WI及PET/MR T2WI在图像质量及融合准确度方面差异均无统计学意义（P均>0.05）;在显示阳性原发灶及阳性淋巴结的清晰度方面,PET/MR T1WI及PET/MR T2WI均优于PET/CT（P均<0.05）。40个阳性原发灶中,PET/MR T2WI对29个原发灶的特征显示多于PET/CT,4个原发灶与PET/CT相仿,7个原发灶较PET/CT少。结论 PET/MR在HNSCC诊断中的应用是可行的,在显示头颈部局部病灶时较PET/CT更具优势。     

骶骨衰竭骨折的18F-FDG PET/CT显像分析

目的 探讨骶骨衰竭骨折的¹⁸F-FDG PET/CT显像特点。方法 回顾性分析接受¹⁸F-FDG PET/CT检查、诊断为衰竭骨折的8例患者的资料。结果 8例患者均发现骶骨有不同程度的异常放射性摄取增高,最大标准摄取值（SUV_max）为2.7~7.2。病变位于骶骨左侧翼4例、双侧骶骨翼及岬部2例、双侧骶骨翼1例、骶骨左侧翼及岬部1例;8例发生骶骨翼的纵行骨折,6例位于S1~2椎体,2例累及S3椎体,3例发生骶骨岬部的横行骨折,2例位于S2椎体,1例位于S3椎体;骶骨骨质密度增高5例、密度未见改变3例。结论 骶骨衰竭骨折的¹⁸F-FDG PET/CT显像有一定特点。     

成人脊柱朗格汉斯细胞组织细胞增生症的18F-FDG PET/CT表现

目的 观察成人脊柱朗格汉斯细胞组织细胞增生症（LCH）的¹⁸F-FDG PET/CT表现。方法 回顾性分析经病理证实的9例成人脊柱LCH患者的¹⁸F-FDG PET/CT表现,评估脊柱病灶数目、分布、密度、边界及最大标准摄取值（SUV_max）。结果 9例LCH共18个病灶位于脊柱,6例单发,3例多发。其中16个病灶¹⁸F-FDG PET/CT表现为不同程度的溶骨性骨质破坏及软组织密度肿块,边界清晰,7个可见边缘硬化,3个病变累及椎管;另2个病灶分别表现为片状稍高密度影及局部骨密度正常。所有病灶¹⁸F-FDG摄取均有不同程度增高,SUV_max为9.07±4.99。结论 成人脊柱LCH的¹⁸F-FDG PET/CT表现具有一定特征性,有助于诊断。     

Whole-Body [18F]FDG-PET/MRI vs. [18F]FDG-PET/CT in Malignant Melanoma

Purpose

To assess the diagnostic performance of simultaneous whole-body 2-deoxy-2-[¹⁸F]fluoro-D-glucose ([¹⁸F]FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) compared to [¹⁸F]FDG PET/x-ray computed tomography (CT) for detection of distant metastatic disease in patients with malignant melanoma.

Procedures

We included patients with malignant melanoma who underwent a single injection [¹⁸F]FDG dual-imaging protocol that included whole-body PET/CT and subsequent whole-body PET/MRI for staging or restaging purposes in a prospective setting. Images from both modalities were analyzed by two rater teams for the presence of metastatic lesions. PET/CT–PET/MRI overall agreement as well as region-based accuracies, sensitivities (Se), and specificities (Sp) were computed.

Results

Between July 2014 and December 2018, 22 patients were enrolled. Interrater agreement and overall accuracy (consensus reading) were 78.8 % (95 % CI 71–84.9) and 96.1 % (95 % CI 92.3–98) for PET/MRI and 78 % (70.2–84.3) and 97.4 % (95 % CI 93.7–98.9) for PET/CT, respectively (P?=?0.42). PET/MRI reached a region-based Se of 89.1 % (95 % CI 79.4–94.5) and a Sp of 100 %, whereas PET/CT showed a region-based Se of 92.7 % (95 % CI 84–96.9) and a Sp of 100 % for the detection of metastatic disease in malignant melanoma.

Conclusions

Whole-body [¹⁸F]FDG-PET/MRI appears to be comparable to [¹⁸F]FDG-PET/CT for lesion detection in patients with malignant melanoma.

     

Positron emission tomography/computed tomography hypermetabolism of Kikuchi–Fujimoto disease mimicking malignant lymphoma: a case report and literature review

Kikuchi–Fujimoto disease (KFD), also known as histiocytic necrotizing lymphadenitis, is a benign, self-limiting inflammatory disorder of unknown etiology and pathogenesis. This report presents a rare case involving a man with ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) hypermetabolism caused by KFD mimicking malignant lymphoma. The PET/CT maximum intensity projection showed multiple hypermetabolic lymphadenopathies and homogeneous FDG uptake in the bone marrow and spleen. Malignant lymphoma was initially suspected. The patient then underwent excision biopsy of one enlarged right cervical lymph node that was selected because it showed the highest FDG uptake in PET/CT, and examination of this biopsy specimen confirmed the diagnosis of KFD. PET/CT is useful for assessing the general condition of patients and can help to select lymph nodes for excision biopsy based on the highest FDG uptake. However, KFD can predispose to localized FDG uptake and limit the specificity of PET/CT by mimicking malignancy. Thus, positive results of PET/CT should be interpreted with caution.     

18F-FDG PET/CT诊断原发性肝癌和肝转移瘤的价值

目的 探讨¹⁸F-FDG PET/CT在原发性肝癌和肝转移瘤诊断中的应用价值。方法 回顾性分析108例肝脏肿瘤患者临床资料、常规影像(超声、增强CT和MRI)及PET/CT资料,病灶¹⁸F-FDG浓集水平高于周围正常肝组织为诊断恶性标准。结果 108例肝脏肿瘤各种影像检查共检出194个病灶,70个肝细胞癌病灶¹⁸F-FDG PET/CT发现34个,最大标准摄取值(SUV_max)为4.95±3.86;23个胆管细胞癌病灶PET/CT发现22个,SUV_max为7.65±3.88;101个肝内转移瘤病灶PET/CT发现97个,SUV_max为9.65±5.34。¹⁸F-FDG PET/CT对肝转移瘤和胆管细胞癌的阳性检出率(96.04%和95.65%)均高于肝细胞癌(48.57%),差异均有统计学意义(P均<0.05);肝转移瘤与肝细胞癌、胆管细胞癌与肝细胞癌之间SUV_max的差异均有统计学意义(P均<0.05)。不同原发肿瘤来源的肝转移灶的SUV_max值差异无统计学意义(F=2.07,P>0.05)。结论 ¹⁸F-FDG PET/CT对原发性肝癌和肝转移瘤的病灶检出率不同,病灶的SUV_max值亦存在差异;在肝脏肿瘤诊断与分期时需科学合理应用¹⁸F-FDG PET/CT。     

PET/CT和MRI术前定位神经节细胞胶质瘤相关药物难治性癫痫

目的 评价¹⁸F-FDG PET/CT脑显像和头颅MRI术前定位神经节细胞胶质瘤（GG）相关药物难治性癫痫的价值。方法 回顾性分析23例药物难治性癫痫、且术后病理证实为GG患者，术前均接受MR及PET/CT检查；定性分析MRI信号特点及PET/CT低代谢范围，与术后CT所示手术区域相对照，分析两种方法术前定位GG相关药物难治性癫痫的价值。结果 23例中，12例致痫灶为单一病理类型，11例为多重病理类型，包括5例GG和皮质发育不良（FCD）、4例GG和皮质胶质增生、1例GG累及海马及1例GG、FCD和海马硬化。23例中，18例MRI显示单一部位实性或囊实性异常信号，其中8例（单一病理类型）与手术切除致痫灶范围完全一致；5例MRI阴性。¹⁸F-FDG PET/CT示8例幕上单一部位葡萄糖代谢减低，均与手术所示GG病灶部位一致；15例幕上多部位代谢减低，其中11例与手术切除范围完全一致。MRI定位准确率34.78%，阳性率78.26%；¹⁸F-FDG PET/CT定位准确率82.61%，阳性率为100%（P均<0.05）。结论 ¹⁸F-FDG PET/CT脑显像术前定位GG相关药物难治性癫痫优于MRI；联合应用二者有助于提高定位精准度。     

SAPHO综合征累及骨及关节99Tcm-MDP SPECT/CT显像表现

目的 观察⁹⁹Tc^m-MDP SPECT/CT显像所示滑膜炎、痤疮、脓疱病、骨肥厚及骨炎(SAPHO)综合征累及骨与关节表现。方法 回顾性分析69例SAPHO综合征患者⁹⁹Tc^m-MDP SPECT/CT资料,以聚类分析法评估SAPHO综合征累及骨、关节模式。结果 根据聚类分析,SAPHO所致骨与关节病变可分为肋骨型(n=19)、脊柱型(n=32)和胸锁关节型(n=18)。共于19例肋骨型检出145处病灶,包括60处肋骨病灶及95处其他病灶,半数以上呈低、中度摄取;半数呈溶骨性骨质破坏、边缘呈低度摄取;少数肋骨密度无明显改变。脊柱型多累及中轴骨 (27/32,84.38%);椎体病变多累及一侧肋椎关节、呈连续性分布及低、中度摄取。胸锁关节型均累及胸锁关节,半数以上病灶位于胸锁关节并呈高度摄取,以"牛头征"和"半牛头征" 为典型表现,多见骨质增生硬化、骨皮质肥厚。结论 SAPHO综合征累及骨关节可分为肋骨型、脊柱型及胸锁关节型。全身骨显像缺乏"牛头征"或"半牛头征"等典型表现时,结合临床表现及SPECT/CT融合显像有助于诊断。     

ECG-gated 18F-FDG positron emission tomography

Aim: ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG)-positron emission tomography (PET) provides information about myocardial glucose metabolism to diagnose myocardial viability. Additional information about the functional status is necessary. Comparison of tomographic metabolic PET with data from other imaging techniques is always hampered by some transfer uncertainty and scatter. We wanted to evaluate a new Fourier-based ECG-gated PET technique using a high resolution scanner providing both metabolic and functional data with respect to feasibility in patients with diseased left ventricles. Methods: Forty-five patients with coronary artery disease and at least one left ventricular segment with severe hypokinesis or akinesis at biplane cineventriculography were included. A new Fourier-based ECG-gated metabolic ¹⁸F-FDG-PET was performed in these patients. Function at rest and ¹⁸F-FDG uptake were examined in the PET study using a 36-segment model. Results: Segmental comparison with ventriculography revealed a high reliability in identifying dysfunctional segments (>96%). ¹⁸F-FDG uptake of normokinetic/hypokinetic/akinetic segments was 75.4 ± 7.5, 65.3 ± 10.5, and 35.9 ± 15.2% (p < 0.001). In segments 70% ¹⁸F-FDG uptake no akinesia was observed. No residual function was found below 40% ¹⁸F-FDG uptake. An additional dobutamine test was performed and revealed inotropic reserve (viability) in 42 akinetic segments and 45 hypokinetic segments. Conclusion: ECG-gated metabolic PET with pixel-based Fourier smoothing provides reliable data on regional function. Assessment of metabolism and function makes complete judgement of segmental status feasible within a single study without any transfer artefacts or test-to-test variability. The results indicate the presence of considerable amounts of viable myocardium in regions with an uptake of 40–50% ¹⁸F-FDG.     

肺转移瘤18F-FDG PET/CT显像分析

目的 分析肺转移瘤的18F-FDG PET/CT显像结果 ,以期提高诊断正确率,减少漏诊和误诊. 方法 对68例肿瘤患者肺转移灶的18F-FDG PET/CT显像结果 进行回顾性分析. 结果 68例CT显示阳性病例中,PET显示阳性18例,部分阳性27例,总阳性率为66.18%;阴性23例,占33.82%.CT发现病灶数目575个,PET显示194个,PET检出率为33.74%.FDG有无摄取以及摄取的程度与转移灶大小有明显关系,与原发肿瘤的来源无关.随着病灶增大,PET阳性率和SUV值均明显增高. 结论 18F-FDG PET对肺转移瘤、尤其是单个转移灶的鉴别诊断价值有限.     

18F-前列腺特异性膜抗原-1007 PET/CT显像、11C-胆碱PET/CT显像及单光子发射计算机断层成像术骨显像对前列腺癌骨转移的诊断价值比较

目的探讨¹⁸F-前列腺特异性膜抗原(PSMA)-1007标记的正电子发射体层显像融合计算机体层显像技术(PET/CT)显像、11C-胆碱(11C-CHO)PET/CT显像及单光子发射计算机断层成像术(SPECT)骨显像在前列腺癌骨转移诊断上的差异。方法回顾性分析2018年9月至2020年7月北部战区总医院核医学科收治的43例男性前列腺癌患者的临床资料,年龄(77.47±11.87)岁,年龄范围为55~89岁。所有患者行¹⁸F-PSMA-1007 PET/CT显像、11C-CHO PET/CT显像及SPECT骨显像检查。分别统计¹⁸F-PSMA-1007 PET/CT显像、11C-CHO PET/CT及SPECT骨显像诊断骨转移的阳性例数和阴性例数,计算三种方法各自的灵敏度、特异度、准确性、阳性预测值、阴性预测值,绘制受试者工作特征(ROC)曲线,计算并比较各自曲线下面积(AUC),评价三种检查方法对前列腺癌骨转移的诊断效能。结果 43例前列腺癌患者中,27例患者出现骨转移。¹⁸F-PSMA-1007 PET/CT显像示26例患者发生骨转移,漏诊1例;11C-CHO PET/CT显像示24例患者发生骨转移,误诊1例,漏诊4例;SPECT骨显像示23例患者发生骨转移,误诊3例,漏诊7例,三者诊断前列腺癌骨转移的灵敏度、特异度、准确性分别为96.3%(26/27)、100%(16/16)、97.7%(42/43);85.2%(23/27)、93.8%(15/16)、88.4%(38/43);74.1%(20/27)、81.3%(13/16)、76.7%(33/43)。¹⁸F-PSMA-1007 PET/CT显像、11C-CHO PET/CT和SPECT骨显像ROC曲线的AUC和95%CI分别为0.981(0.885~1.000)、0.913(0.763~0.967)、0.777(0.624~0.889)。三种检查的AUC曲线下面积进行两两比较,差异均有统计学意义(P<0.05)。采用Wilcoxon秩和检验对27例患者三种方法检出的骨转移灶的数量进行两两比较发现,¹⁸F-PSMA-1007 PET/CT显像与SPECT骨显像比较,差异有统计学意义(Z=-2.484,P=0.013),¹⁸F-PSMA-1007 PET/CT显像与11C-CHO PET/CT显像比较,差异无统计学意义(Z=-0.160,P=0.873);11C-CHO PET/CT显像与SPECT骨显像比较,差异有统计学意义(Z=-2.085,P=0.037)。结论 PET/CT显像较SPECT骨显像能发现更多的骨转移灶。¹⁸F-PSMA-1007 PET/CT显像对前列腺癌骨转移诊断的灵敏度、特异度及准确性高于其他两种检查方式。在低前列腺特异性抗原(PSA)的情况下,能够精确地对前列腺癌骨转移做出诊断。     

中枢神经系统疾病的18F-FDG PET显像——附17例PET与CT、MRI和EEG对照

目的 地＾１８Ｆ－ＦＤＧＰＥＴ在中枢神经系统疾病临床诊断中应用的初步体会作一介绍。方法 ＾１８Ｆ－ＦＤＧＰＥＴ检查共计１７例,所有患者静脉注射＾１８Ｆ－脱氧葡萄糖（ＦＤＧ）１０ｍＣｉ后４０分钟进行脑＾１８Ｆ－ＦＤＧ正电子发射断层显像（ＰＥＴ）。其结果与同期的ＣＴ、ＭＲＩ、ＥＥＧ结果进行比较。结果 在１０例癫痫发作间歇期病人中,４０％的病例＾１８Ｆ－ＦＤＧＰＥＴ显示病侧局部脑叶葡萄代谢正常、脑梗塞、     

A case of human pancreatic eurytremiasis

This study provides the first comprehensive imaging report of human pancreatic eurytremiasis. A 43-year-old man with obstructive jaundice and a pancreatic tumor was referred for diagnosis and treatment. Serum aspartate aminotransferase, alanine aminotransferase, and gamma-glutamyl transpeptidase were elevated. Computed tomography (CT) revealed a multilocular cystic lesion with delayed enhanced area in the pancreas head. On magnetic resonance imaging, the tumor was hyperintense on diffusion-weighted image, and the apparent diffusion coefficient value of the tumor was lower than that of the normal pancreatic parenchyma. Positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-d-glucose integrated with computed tomography (¹⁸F-FDG PET/CT) revealed abnormally increased uptake of ¹⁸F-FDG in the tumor. A subtotal stomach-preserving pancreaticoduodenectomy was performed on the preoperative diagnosis of pancreatic carcinoma accompanied by branch duct-type intraductal papillary mucinous neoplasm. Multifocal granulomatous lesions with necrotic areas including many parasite eggs were seen on the histology. The final diagnosis was pancreatic eurytremiasis.

     

人工髋关节置换术后并发症影像学表现

目的 探讨人工髋关节置换术后并发症的影像学表现。方法 回顾性分析28例(共31例次)人工髋关节置换术后出现并发症而接受髋关节翻修术患者,观察其影像学表现。结果 31例次中,术后诊断股骨头脱位4例次,X线平片表现为股骨头位于髋臼外;无菌性松动22例次,X线表现为假体周围2~30 mm的透亮带,其中,假体周围慢性肉芽肿性炎CT/MRI表现为骨质破坏并软组织肿块;感染4例次,X线表现为假体周围2~4 mm的轮廓与假体形态不一致的透亮带,MRI表现为感染区软组织肿胀,见环形强化病灶;异位骨化1例次,X线表现为髋臼假体周围软组织大量骨化影。结论 假体周围透亮带是人工髋关节置换术后关节松动最重要的X线表现,CT/MRI有助于区分无菌性松动中的假体慢性肉芽肿性炎、以鉴别感染性和无菌性松动。     

18F-FDG PET/CT在肾脏肿瘤诊疗中的应用

目的评价18F-FDG PET/CT在肾脏肿瘤诊断和治疗中的价值。方法对30例CT或MRI确诊或怀疑肾脏肿瘤的患者行18F-FDG PET/CT显像,22例患者行延迟显像。所有肾脏肿瘤均经手术或穿刺活检后病理确诊。评价18F-FDG PET/CT对患者治疗方案的影响。结果 30例中,肾细胞癌(RCC)24例,肾神经内分泌肿瘤1例,淋巴瘤3例,肺癌肾转移1例,肾脏炎性病变1例。PET/CT诊断肾脏肿瘤的灵敏度为89.66%(26/29),特异度为100%(1/1),准确率为90.00%(27/30),阳性预测值为100%(26/26),阴性预测值为25.00%(1/4)。PET/CT检出肾癌伴肾门淋巴结转移2例,远处转移5例。8例(RCC 4例、肾淋巴瘤3例及肾转移癌1例)接受PET/CT后治疗方案发生改变。显像阳性肾癌患者Fuhrman分级高于阴性患者(P<0.05),显像阳性肾癌平均直径大于阴性者(P<0.05)。22例肾癌早期最大标准摄取(SUVmax)值与延迟显像SUVmax值差异无统计学意义(P>0.05)。结论 18F-FDG PET/CT可准确显示肾肿瘤患者局部病变及远处转移。对可疑肾淋巴瘤及肾转移瘤患者应行18F-FDG PET/CT显像,以明确分期并寻找原发灶。